ASCO 2022

Paradigm shift in breast cancer: Where do we use the treatment option? How do we test HER2 status? How can we manage toxicity?

CDK4/6i switch: who benefits from switching the CDK4/6 inhibitor?

What are the cosenquences of the new OS data for CDK4/6 inhibitor therapy?

Transatlantic differences in ADC side effects management

More data needed: Are the results clinical meaningful? How can SG fit in the therapy algorithm?

What clincial value has statistical signifcance? How can we improve trial design to become statistical and clinical significant?

Patients perspectives: ADCs - how do manage the new, smart chemotherapies?

Determining HER2 receptor expression: How do we target the HER2-low subtype?

ADCs & CDK4/6i - paradigm shifts and therapy switches in metastatic breast cancer

How to determine progress of disease? How to proceed therapy after CDK4/6i inhibitor? When should we change the endocrine combination partner?

Impressive and practice changing data of ADCs mark the beginning of a long success story

Combination of ctDNA and TKa assesment may improve outcome prediction of RIB+LET treatment

Exciting advances across a wide subset of breast cancers

Exciting and practice changing news for HR+/Her2low MBC patients

New agents for the clincial practice

Option for overcoming endocrine resistance?

Gamechanger in breast cancer

Revolution in the field of HR+ disease

Oligometastasis: no advantage of additional radiotherapy

New standard of care for HR+/Her2low patients

Improvment of PFS & OS with activated alteration PIK3CA/AKT1/PTEN pathway.

Patritumab Deruxtecan: HER3-targeted ADC in HER3 -expressing mBC

Additional administration of ribociclib improves PFS after prior CDK4/6i therapy.

ADC: future therapeutic option in advanced HR+/HER2 BC

Benefit of CDK4/6 Switch after Progression

First evidence on benefit of CDK4/6 inhibitors beyond progression

Possible explanations of the negative study

SG is a new therapy option for HR+/HER2- MBC patients

Discontiunation of trial is disappointing despite negative results

Combi SERD + Palbo reduces proliferation better than SERD + anastrozole

My ASCO22 highlights in metastatic breast cancer

Endocrine therapy alone is important in treatment of elderly patients

Fascinating data of ADCs in breast cancer at ASCO22

Disappoiting final OS data and its implications for our patients

Breakthrough news with antibody drug conjugate

No changes in clinical practice after new CDK4/6i-data

New SoC for large subpopulation of breast cancer patients

Practice changing data

No effect for local treatment of metastasis

Palbociclib - Overall survival data

SG may be a good option for pre-treated HR+/Her2- pts

T-DxD should be the new SoC for Her2low MBC patients

Sacituzumab govitecan improves PCr in patients with localized TNBC

Good therapeutic option in HR+ HER2- mBC after failure of endocrine therapy

Smart chemotherapy improves PFS

Noutăți inovatoare cu conjugatul de medicamente cu anticorpi

Nowy standard dla znaczącej subopulacji chorych na raka piersi

Il sacituzumab govitecan migliora il PFS nei tumori endocrino-responsivi

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po progresji

Les nouvelles données impressionnantes des ADC à l’ASCO 2022 : le début d'une longue histoire de succès

Novità entusiasmanti e practice changing per le pazienti con tumore mammario metastatico HR+/Her2low

La valutazione combinata di ctDNA e TKa può aiutare a migliorare la selezione delle pazienti trattate con RIB+LET

ADCs en cáncer de mama con receptores hormonales positivos

SG come nuova opzione di cura per le pazienti con tumore mammario metastatico HR+/HER2-

I nuovi impressionanti risultati degli ADC a l’ASCO 2022 : l’inizio di una lunga storia di successi.

Una rivoluzione per il tumore mammario endocrino-responsivo ed HER2 low

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Neoadjuvant Pembro decreased RCB. SG - first promising ADC in early TNBC!

Adding towards deescalation in luminal A EBC by omitting radiotherapy

CT benefit for elderly patients, if they are able to complete therapy.

Long term overall survival benefit of Denosumab in addition to improved bone health

Ovarian function suppression - it is here to stay!

My ASCO22 highlights in early breast cancer

High concordance of local, central IHC and RT-PCR for ER, PR and HER2

Combi SERD + Palbo redzuert proliferation better than SERD + anastrozole

Immunotherapy - Part 2

Molecular landscape - Part 2

Immunotherapy - Part 1

Molecular landscape - Part 1

New treatment options for METexon 14 skipping: amivantamab

COSMIC-021: Not practice-changing, but interesting results

New components and therapies for advanced NSCLC

CLN-081 is a promising new agent for EGFR exon 20 insertion NSCLC

Options after progression to chemo/IO and for KRASG12C mut

Strategies for PD-L1 > 50%

CLN-081 for patients with metastatic NSCLC and an EGFRexon20 insertion

A chemo-free option in patients with EGFR-mutation

Bispecific Antibodies - the cMET field is moving

Is adagrasib an alternative to sotorasib?

PD-L1 over 50%: Chemo-IO or IO?

Promising results for pre-treated patients with KRASG12C mutation

Amivantamab as a future option for METex14 patients?

Multiple aquired resistance mutations may drive disease progression

In the second line: Options for Immunotherapy resistance and KRAS mutations

New option in patients harboring METex14 mutation

Role of IO and chemo-IO in patients with PD-L1 > 50%

KRASG12C mutation: Adagrasib is comparabale to sotorasib

COSMIC-021: Nicht praxisverändernd, aber interessante Resultate

Segunda Linea: opciones tras resistencia a inmunoterapia y mutaciones de KRAS

CLN-081 voor patienten met gemetastaseerd NSCLC en een EGFRexon20 insertie

Veelbelovende resultaten voor voorbehandelde patienten met een KRAS G12C mutatie

Nieuwe behandelopties voor METexon 14 skipping: amivantamab

Bispezifische Antikörper - Neues von CHRYSALIS

Une nouvelle option, l’amivantamab, en situation de délétion dans l’exon 14 de MET

Was tun nach Versagen einer Chemoimmun-Therapie?

Nuevas terapias para el CPCNP avanzado

PD-L1 über 50 % - was tun?

L’adagrasib, inhibiteur de la mutation KRASG12C: une efficacité comparable à celle du sotorasib?

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 > 50%

Neoadjuvant and adjuvant therapy - Part 1

Neoadjuvant and adjuvant therapy - Part 2

Perspectives on multimodality

NADIM-II strengthens the findings from CheckMate-816

New treatment approaches in Stage III

CheckMate-816: Neoadjuvant therapy

A new option in neoadjuvant chemoimmunotherapy

Chimiothérapie néoadjuvante des stades III , vers un nouveau standard de soins

Neue Ansätze im Stadium III

Immuncheckpoint-inhibitor therapy

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is here to stay

No benefit for tiragolumab / novel anti-PD-1 mAB serplulimab effective

SKYSCRAPER-02: Subgroups could be important

Le Tiragolumab n’apporte pas de bénéfice à la chimioimmunothérapie de première ligne/ Une nouvelle phase III en faveur de la chimio immunothérapie de première ligne

PARP inhibitors in mCRPC: Do we need more genetic testing?

mHSPC: Transatlantic differences in genetic testing & updates in doublets vs. triplets

mCRPC: LuPSMA - new treatment option in mCRPC

PFS good surrogate endpoint for overall survival

SHR3680 - do we need a new androgen receptor inhibitor

Value of triple-therapy - complimentary study to ARASENS trial

Frequent imaging for early detection of metastases in nmCRPC.

Arbiraterone + Olaparib: Is it synergistic?

Lu-PSMA in the third line

Surrogate endpoints in mHSPC

GGT impacts PCa patients care

TheraP shows no difference in overall survival between cabazitaxel and LuPSMA

SUVmean is highly predictive of better PFS and OS

The efficacy of doublets in mHSPC

Further updates from the VISION trial

Ongoing trial invetiagting the impact of Bavdegalutamide on Arbiraterone restistance in pts with PCa

Lu-PSMA effective regardless of prior or concomitant therapy

Phase 1 study on combining LuPSMA treatment with immunotherapy

ADT alone is no longer standard of care

LuPSMA & cabazitaxel are better than SoC alone

The highlights in GU cancers of ASCO22

SUV mean at PET images as a prognostic tool for PSMA treatment

3 year overall survival of TheraP study

No big scoop, but encouraging results

Kvantifiering av PMSA PET upptaget som prognostisk markör i VISION studien

Lo mas destacado en tumores GU en ASCO 2022

Pas de nouvelles sensationnelles mais des données encourageantes

Tidigare endpoints I mHSPC studier

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas 1 prövning

Treårs överlevnadsresultat i TheraP studien.

EVEREST: Inisghts from the negative trial

The relevance of quality of life in kidney cancer!

Combination Therapy is State of the Art in Metastatic Renal Cell Carcinoma.

What are the consequences for future trial design?

PSMA-PET may improve imaging of clear cell RCC

The highlights in GU cancers of ASCO22

Clear evidence for durable benefit for patients with von Hippel-Lindau disesase

Importance of health related quality of life

QoL & DepOR correlate with clinical outcomes - reminder for future trial designs

Combi Axi + Pembro also successful with good risk profile

Depth of remission in firstline

Belzutifann shows good tumor activity in renal cancer

Should Everolimus be revisited for high-risk patients?

Should we be looking at Everolimus in the future?

Pas de nouvelles sensationnelles mais des données encourageantes

Lo mas destacado en tumores GU en ASCO 2022

New data on TKi utilization in bladder cancer

The role of systemic treatment in the pre-operative setting and updates on Avelumab maintenance

ADCs: do we enter a new era of therapy for urothelial cancer?

Maintenance concepts

ADCs: News from ASCO 2022

No big scoop, but encouraging results

The highlights in GU cancers of ASCO22

BCG failure

My highlights of metastasized urothelial cancer

Perioperative immuno-chemotherapy in MIBC

The end of of VEGF-targeted therapy in urothelial cancer?

Exciting future for ADCs

Investigating sasanlimab in BCG-unresponsive NMIBC

My highlights in localized urothelial cancer

Lo mas destacado en tumores GU en ASCO 2022

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το ASCO 2022

Few testicular tumors after 5 years

Systemic therapy

Precision oncology - NTRK worth to search the patients

Radiotherapy as a new standard for cisplatin ineligible patients

Opportunities & challenges of cancer genetics

News from Sarcoma